Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 422

1.

Moyamoya syndrome associated with neurofibromatosis Type 1: perioperative and long-term outcome after surgical revascularization.

Koss M, Scott RM, Irons MB, Smith ER, Ullrich NJ.

J Neurosurg Pediatr. 2013 Apr;11(4):417-25. doi: 10.3171/2012.12.PEDS12281. Epub 2013 Feb 1.

PMID:
23373626
2.

Pial synangiosis in patients with moyamoya syndrome and sickle cell anemia: perioperative management and surgical outcome.

Smith ER, McClain CD, Heeney M, Scott RM.

Neurosurg Focus. 2009 Apr;26(4):E10. doi: 10.3171/2009.01.FOCUS08307.

PMID:
19335126
3.

Clinical characteristics and long-term outcomes of moyamoya syndrome associated with neurofibromatosis type 1.

Han C, Yang WZ, Zhang HT, Ye T, Duan L.

J Clin Neurosci. 2015 Feb;22(2):286-90. doi: 10.1016/j.jocn.2014.05.046. Epub 2014 Oct 28.

PMID:
25443089
4.

Down syndrome and moyamoya: clinical presentation and surgical management.

See AP, Ropper AE, Underberg DL, Robertson RL, Scott RM, Smith ER.

J Neurosurg Pediatr. 2015 Jul;16(1):58-63. doi: 10.3171/2014.12.PEDS14563. Epub 2015 Apr 3.

PMID:
25837890
5.

Moyamoya syndrome associated with Down syndrome: outcome after surgical revascularization.

Jea A, Smith ER, Robertson R, Scott RM.

Pediatrics. 2005 Nov;116(5):e694-701.

PMID:
16263984
6.

Long-term outcome in children with moyamoya syndrome after cranial revascularization by pial synangiosis.

Scott RM, Smith JL, Robertson RL, Madsen JR, Soriano SG, Rockoff MA.

J Neurosurg. 2004 Feb;100(2 Suppl Pediatrics):142-9.

PMID:
14758941
7.

Surgical Treatment for Patients with Moyamoya Syndrome and Type 1 Neurofibromatosis.

Porras JL, Yang W, Garzon-Muvdi T, Xu R, Blakeley J, Belzberg A, Caplan JM, Khalid S, Colby GP, Coon AL, Tamargo RJ, Ahn ES, Huang J.

World Neurosurg. 2017 Mar;99:19-25. doi: 10.1016/j.wneu.2016.11.051. Epub 2016 Nov 19.

PMID:
27876659
8.
9.

Treatment of Moyamoya disease in the adult population with pial synangiosis.

Lin N, Aronson JP, Manjila S, Smith ER, Scott RM.

J Neurosurg. 2014 Mar;120(3):612-7. doi: 10.3171/2013.11.JNS131027. Epub 2014 Jan 3.

PMID:
24405066
10.

Progression of disease in unilateral moyamoya syndrome.

Smith ER, Scott RM.

Neurosurg Focus. 2008;24(2):E17. doi: 10.3171/FOC/2008/24/2/E17.

PMID:
18275294
11.

Unstable moyamoya disease: clinical features and impact on perioperative ischemic complications.

Funaki T, Takahashi JC, Takagi Y, Kikuchi T, Yoshida K, Mitsuhara T, Kataoka H, Okada T, Fushimi Y, Miyamoto S.

J Neurosurg. 2015 Feb;122(2):400-7. doi: 10.3171/2014.10.JNS14231. Epub 2014 Nov 28.

PMID:
25423271
12.

Pial synangiosis in patients with moyamoya younger than 2 years of age.

Jackson EM, Lin N, Manjila S, Scott RM, Smith ER.

J Neurosurg Pediatr. 2014 Apr;13(4):420-5. doi: 10.3171/2014.1.PEDS13251. Epub 2014 Feb 14.

PMID:
24527861
13.

Surgical treatment of moyamoya syndrome in patients with sickle cell anemia: outcome following encephaloduroarteriosynangiosis.

Hankinson TC, Bohman LE, Heyer G, Licursi M, Ghatan S, Feldstein NA, Anderson RC.

J Neurosurg Pediatr. 2008 Mar;1(3):211-6. doi: 10.3171/PED/2008/1/3/211.

PMID:
18352765
14.

Outcome of repeat revascularization surgery for moyamoya disease after an unsuccessful indirect revascularization. Clinical article.

Pandey P, Steinberg GK.

J Neurosurg. 2011 Aug;115(2):328-36. doi: 10.3171/2011.3.JNS101908. Epub 2011 Apr 29.

PMID:
21529138
15.

[Pial synangiosis for moyamoya disease. The Bordeaux experience].

Jecko V, Penchet G, Champeaux C.

Neurochirurgie. 2016 Aug;62(4):190-6. doi: 10.1016/j.neuchi.2015.12.004. Epub 2016 Apr 23. French.

PMID:
27113323
16.

Pial synangiosis for moyamoya syndrome in children with sickle cell anemia: a comprehensive review of reported cases.

Kennedy BC, McDowell MM, Yang PH, Wilson CM, Li S, Hankinson TC, Feldstein NA, Anderson RC.

Neurosurg Focus. 2014 Jan;36(1):E12. doi: 10.3171/2013.10.FOCUS13405.

PMID:
24380478
17.

Encephaloduroarteriosynangiosis and encephalomyoarteriosynangiosis for treatment of moyamoya syndrome in pediatric patients with sickle cell disease.

Griessenauer CJ, Lebensburger JD, Chua MH, Fisher WS 3rd, Hilliard L, Bemrich-Stolz CJ, Howard TH, Johnston JM.

J Neurosurg Pediatr. 2015 Jul;16(1):64-73. doi: 10.3171/2014.12.PEDS14522. Epub 2015 Apr 3.

PMID:
25837886
18.

Clinical features and long-term outcomes of moyamoya disease: a single-center experience with 528 cases in China.

Liu XJ, Zhang D, Wang S, Zhao YL, Teo M, Wang R, Cao Y, Ye X, Kang S, Zhao JZ.

J Neurosurg. 2015 Feb;122(2):392-9. doi: 10.3171/2014.10.JNS132369. Epub 2014 Nov 28.

PMID:
25423267
19.

Discovery of asymptomatic moyamoya arteriopathy in pediatric syndromic populations: radiographic and clinical progression.

Lin N, Baird L, Koss M, Kopecky KE, Gone E, Ullrich NJ, Scott RM, Smith ER.

Neurosurg Focus. 2011 Dec;31(6):E6. doi: 10.3171/2011.10.FOCUS11228.

PMID:
22133171
20.

Effectiveness of surgical revascularization for stroke prevention in pediatric patients with sickle cell disease and moyamoya syndrome.

Yang W, Xu R, Porras JL, Takemoto CM, Khalid S, Garzon-Muvdi T, Caplan JM, Colby GP, Coon AL, Tamargo RJ, Huang J, Ahn ES.

J Neurosurg Pediatr. 2017 Sep;20(3):232-238. doi: 10.3171/2017.1.PEDS16576. Epub 2017 Jul 7.

PMID:
28686127

Supplemental Content

Support Center